

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number
WO 02/37937 A2

(51) International Patent Classification: Not classified

(21) International Application Number: PCT/US01/49952

(22) International Filing Date:
7 November 2001 (07.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/246,391 7 November 2000 (07.11.2000) US
60/246,392 7 November 2000 (07.11.2000) US-

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Lawrenceville-Princeton Rd., Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BISACCHI, Gregory, S.** [US/US]; 130 Mountain Road, Ringoes, NJ 08551 (US). **SUTTON, James, C., Jr.** [US/US]; 8 Stonelea Drive, Princeton Junction, NJ 08550 (US). **WU, Shung, C.** [US/US]; 24 Bertrand Dr., Princeton, NJ 08540 (US).

(74) Agents: **ALGIERI, Aldo, A.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Lawrenceville-Princeton Rd., Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/37937 A2

(54) Title: ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS

(57) Abstract: Compounds of formula I and II, or pharmaceutically-acceptable salts thereof, are useful as inhibitors of Factor VIIa, Factor IXa, Factor Xa, Factor FXIa, trypsin, and urokinase, wherein ring B is phenyl or pyridyl, L is a linker, and R₁, R₂₇, W, Z₁, and Z₂ are as defined in the specification.

ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS

Related applications

This application claims the benefit of U.S. Provisional Application Nos. 60/246,391 and 60/246,392, both filed November 7, 2000, the contents of which are
5 incorporated herein by reference.

Field of the Invention

The present invention relates to acid derivatives that are inhibitors of serine proteases such as Factor VIIa, Factor IXa, Factor Xa, Factor FXIa, tryptase, and
10 urokinase. These acid derivatives are useful as anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in treating cancer.

Background of the Invention

Under normal conditions, the coagulation system is naturally balanced in favor
15 of anticoagulation by a number of proteins circulating in the blood. These proteins include antithrombin III, a serine-protease inhibitor, and protein C, a vitamin-K dependent protein formed in the liver. When injury or trauma occurs, thrombin is produced at precise levels through an ordered series of reactions. Thrombin is a proteolytic enzyme that occupies a central position in the coagulation process. Thrombin
20 catalyzes the conversion of fibrinogen to fibrin, is a key effector enzyme for blood clotting, and also is pivotal for other functions, such as activation of helper proteins (including Factors V and VIII and thrombomodulin), and its own activation. Disturbances in the natural balance between pro- and anti-coagulant forces may result in bleeding or thrombotic diseases.

25 The series of reactions leading to thrombin production involve a number of coagulation factors present in the blood as precursors (*e.g.*, Factors VII – XII). When the coagulation system is triggered (*e.g.*, when trauma occurs), the coagulation factors are transformed into activated factors (*e.g.*, Factors VIIa, IXa, Xa, XIa, etc.). Factor VII

forms a complex with a membrane protein called tissue factor, to which Factor VIIa tightly binds. Thus, Factor VIIa is present as a complex bound to tissue factor. When triggered, the coagulation factors and tissue factor complexes undergo an ordered chain of reactions that ultimately lead to conversion of Factor X to Factor Xa, and Factor Xa
5 catalyzes the conversion of prothrombin to thrombin.

An elevated plasma level of coagulation factors, particularly Factor VIIa, is a risk factor for fatal myocardial infarction and associated with coronary artery disease and other abnormalities of the coagulation system, *e.g.*, thrombosis, ischemic vascular disease, intravascular clotting, stroke, embolisms, and so forth. Accordingly,
10 antithrombotic agents have been researched and developed for use in treating cardiovascular and other diseases. Presently established antithrombotic agents include heparin, coumarin, and aspirin, among others. There are, however, limitations with these agents. For example, both heparin and coumarin have a highly-variable dose-related response, and their anticoagulant effects must be closely monitored to avoid a risk of
15 serious bleeding. The erratic anticoagulant response of heparin is likely due to its propensity to bind non-specifically to plasma proteins. Aspirin has a limited efficacy and at high doses presents a risk of gastrointestinal bleeding. Thrombin inhibitors and their drawbacks are further discussed in WO 96/20689 to duPont Merck Pharmaceutical Co.

As may be appreciated, those in the field of pharmaceutical research continue to
20 seek to develop new compounds and compositions having increased effectiveness and bioavailability and/or having fewer side effects. *See, e.g.*, Jakobsen *et al.*, "Inhibitors of the Tissue Factor/Factor VIIa-induced Coagulation: Synthesis and In vitro Evaluation of Novel Specific 2-aryl Substituted 4H-3,1-benzoxazin-4-ones," Bioorganic & Medicinal Chemistry, Vol. 8 (August 2000), at pp. 2095-2103; and J. Hirsh *et al.*, "Thrombosis,
25 New Antithrombotic Agents," Lancet, Vol. 353 (April 24, 1999), at pp. 1431-36. There is particularly an interest in developing agents that can selectively and directly inhibit key factors in the complicated coagulation process. Compounds effective in inhibiting Factor Xa are described in U.S. Pat. applications Serial No. 09/478,632, filed January 6, 2000,

Serial No. 09/633,751, filed August 7, 2000, and Serial No. 09/496,571, filed February 2, 2000. Compounds effective in inhibiting Factors VIIa, Xa, as well as tryptase and urokinase are described in U.S. Pat. application Serial No. 09/458,847, filed December 13, 1999. The above referenced '632, '751, '571, and '847 applications show lactam
5 compounds and are each assigned to the present assignee with common inventors herewith. Factor Xa inhibitors are also disclosed in PCT applic. WO 98/57937 to the duPont Merck Pharmaceutical Co.

PCT patent application WO 99/41231 to Ono Pharmaceuticals Inc., ("Ono") discloses a series of amidino derivatives such as 2-(3-(4-amidinophenylcarbamoyl)-
10 naphthalen-2-yl)-5-((2,2-methylpropyl)carbamoyl benzoic acid, which are claimed to be Factor VIIa inhibitors. The Ono application is discussed in Kohrt *et al.*, "An Efficient Synthesis of 2-(3-(4-Amidinophenylcarbamoyl)naphthalen-2-yl)-5-((2,2-methylpropyl)carbamoyl benzoic acid: a Factor VIIa Inhibitor Discovered by the Ono
15 Pharmaceutical Company," Tetrahedron Letters, Vol. 41 (June 2000), at pp. 6041-44, which reports that Ono fails to fully describe an effective method for making the titled compound. Inhibitors of Factor VIIa are also reported in WO 01/44172 to Axys Pharm. Inc. PCT patent application WO 98/47876 to Akzo Novel N.V., published October 29, 1998, discloses certain bicyclic groups such as isoquinoline groups which reportedly are advantageous for promoting pharmacological properties, and isoquinoline-containing
20 compounds are disclosed in WO 94/29273 to SmithKline Beecham Corp. Biphenyl compounds and/or acid substituted bicyclic compounds are also disclosed in US Pat. No. 5,612,341, US Pat. No. 6,248,767 B1, US Pat. No. 3,995,045, EP patent application 0 206 567 A2 to Warner Lambert Co., and WO 01/70678 to Merck Patent GmbH.


The patents, patent applications, and articles cited above are incorporated herein
25 by reference.

The present invention provides acid-based compounds useful as inhibitors of Factor VIIa, Factor IXa, Factor Xa, Factor FXIa, tryptase, and urokinase.

Summary of the Invention

Acid derivatives are provided that are inhibitors of serine proteases having the Formula I or II:

5



or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which:

ring B is phenyl or pyridyl;

W is selected from C₂₋₁₀alkyl, C₂₋₁₀alkenyl, substituted C₂₋₁₀alkyl, substituted C₂₋

10 ₁₀alkenyl, -C(=O)NR₉R₁₀, -OR₉, -CO₂R₉, -C(=O)R₉, -SR₉, -S(O)_pR₉, -NR₉R₁₀,
-NR₉SO₂R₁₀, -NR₉CO₂R₁₀, -NR₉C(=O)R₁₀, -SO₂NR₉R₁₀, -NR_{9a}SO₂NR₄R₅,
-NR_{9a}C(=O)NR₄R₅, heterocyclo, heteroaryl, aryl, and cycloalkyl;

Z₁ is selected from a 5 to 7-membered monocyclic or 8 to 11-membered bicyclic aryl,
heteroaryl, heterocyclo, or cycloalkyl;

15 Z₂ is a fully saturated carbocyclic or heterocyclic 5-7 membered monocyclic or 7-11
membered bicyclic ring;

L is -(CR₁₈R₁₉)_s-Y-(CR_{18a}R_{19a})_t-;

Y is selected from -C(=O), -C(=O)NR₁₃-, -NR₁₃C(=O)-, -NR₁₃CR₁₄R₁₅-, -CR₁₄R₁₅-
NR₁₃-, and -CR₁₃R₁₄-CR₁₅R₁₆-;

20 R₁ and R₂ (i) are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl, heterocyclo, or cycloalkyl; or
(ii) are taken together to form a five-to-seven membered fully saturated heterocyclo
optionally substituted with one to two R₂₆;

- R_3 and R_4 (i) are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroaryl, aryl, heterocyclo, and cycloalkyl; or (ii) are taken together to form an aryl, heteroaryl, cycloalkyl, or heterocyclo, wherein when R_3 and R_4 individually or together form a heteroaryl, aryl, heterocyclo, or cycloalkyl, said
- 5 cyclic group is optionally substituted with up to two R_{26} ;
- R_5 and R_6 are independently selected from hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, $-C(=O)H$, acyl, $-CO_2H$, and alkoxycarbonyl, provided that at least one of R_5 and R_6 is hydrogen;
- R_7 is attached to any available carbon or nitrogen atom of Z and is selected from
- 10 hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, $-C(=O)H$, acyl, $-CO_2H$, alkoxycarbonyl, sulfonyl, sulfonamido, aryl, heteroaryl, heterocyclo, or cycloalkyl, except when Z is phenyl, W is OCH_3 , s is 0 and Y is $-CH_2-CH_2-$, then R_7 is not phenyloxy;
- 15 R_8 is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocyclo, cycloalkyl, or alkyl substituted with $-OC(=O)R_{24}$ or $-OC(=O)O-R_{24}$, wherein R_{24} is alkyl, substituted alkyl, or cycloalkyl, provided that R_8 is not phenyl when W is methoxy;
- R_9 , R_{9a} , and R_{10} are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted
- 20 heteroalkyl, aryl, heteroaryl, heterocyclo, and cycloalkyl; or alternatively (ii) R_9 and R_{10} may be taken together to form a five-to-seven membered heteroaryl or heterocyclo, except when W is $-S(O)_pR_9$, then R_9 is not hydrogen;
- R_{13} , R_{14} , R_{15} , R_{16} , R_{18} , R_{18a} , R_{19} , and R_{19a} are selected from hydrogen, lower alkyl, hydroxy, or lower alkyl substituted with hydroxy or halogen;
- 25 R_{26} and R_{27} (i) are at each occurrence independently selected from hydrogen, OR_{30} , $NR_{31}R_{32}$, $NR_{31}SO_2R_{32a}$, alkyl, alkenyl, substituted alkyl, substituted alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, alkylthio, $-C(=O)H$, acyl, $-CO_2H$, alkoxycarbonyl, sulfonamido, sulfonyl, and phenyl, or (ii) two of R_{26} and/or two of R_{27} may be taken together to form a fused benzo ring, a fused heteroaryl, a fused

- cycloalkyl, or a fused heterocycle other than a five or six membered heterocycle having as its heteroatoms two oxygen atoms;
- R_{30} at each occurrence is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, and phenyl;
- 5 R_{31} and R_{32} at each occurrence are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, and cycloalkyl;
- R_{32a} is alkyl, substituted alkyl, alkenyl, substituted alkenyl, or cycloalkyl;
- m is 0, 1 or 2 when ring B is phenyl and 0 or 1 when ring B is pyridyl;
- p and q are independently 1 or 2; and
- 10 s and t are independently 0, 1 or 2.

Included within the scope of the invention are pharmaceutical compositions for treating a serine protease disease, an inflammatory or immune condition, or cancer, comprising at least one compound of formula I or II, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

15 Also included in the invention are methods of treating such diseases comprising administering to a mammal in need of such treatment at least one compound of formula I or II, or a pharmaceutically acceptable salt, hydrate or prodrug thereof. Further included in the invention are compositions for use as anticoagulants during the preparation, use,

20 storage, or fractionation of blood and methods of maintaining blood in the fluid phase during its preparation, use, storage, or fractionation.

Detailed Description of the Invention

The following are definitions of terms used in this specification. The initial

25 definition provided for a group or term herein applies to that group or term throughout this specification, individually or as part of another group, unless otherwise indicated.

The term "alkyl" refers to straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms. Lower alkyl groups, that is, alkyl groups of 1 to 4 carbon atoms, are most preferred.

When numbers appear in a subscript after the symbol "C", the subscript defines with more specificity the number of carbon atoms that a particular group may contain. For example, "C₁₋₆alkyl" refers to straight and branched chain alkyl groups with one to six carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, and so forth.

The term "substituted alkyl" refers to an alkyl group as defined above having one, two, or three substituents selected from the group consisting of halo, alkenyl, alkynyl, nitro, cyano, hydroxy, alkoxy, alkylthio, -CO₂H, -C(=O)H, -CO₂-alkyl, -C(=O)alkyl, -S(O)₂(alkyl), keto (=O), aryl, heteroaryl, heterocyclo, and cycloalkyl, including phenyl, benzyl, phenylethyl, phenyloxy, and phenylthio. The substituents for "substituted alkyl" groups may also be selected from the group consisting of -NR'R", -C(=O)NR'R", -CO₂NR'R", -NR'CO₂R", -NR'C(=O)R", -SO₂NR'R", and -NR'SO₂R", wherein each of R' and R" is independently selected from hydrogen, alkyl, cycloalkyl, and alkyl substituted with one to two of alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, hydroxy, alkoxy, alkylthio, amino, alkylamino, phenyl, benzyl, phenyloxy, and benzyloxy. Alternatively, R' and R" may together form a heterocyclo or heteroaryl ring. When a substituted alkyl includes an aryl, heterocyclo, cycloalkyl, or heteroaryl substituent, said ringed systems are as defined below and thus may have zero, one, two, or three substituents, also as defined below.


When the term "alkyl" is used in conjunction with another group, e.g., arylalkyl, hydroxyalkyl, etc., the term defines with more specificity a particular substituent that a substituted alkyl will contain. For example, arylalkyl refers to a substituted alkyl group having from 1 to 12 carbon atoms and at least one aryl substituent, and "lower arylalkyl" refers to substituted alkyl groups having 1 to 4 carbon atoms and at least one aryl substituent.

The term "alkenyl" refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one double bond. Alkenyl groups of 2 to 6 carbon atoms and having one double bond are most preferred.

The term "alkynyl" refers to straight or branched chain hydrocarbon groups having 2 to 12 carbon atoms and at least one triple bond. Alkynyl groups of 2 to 6 carbon atoms and having one triple bond are most preferred.

The term "alkylene" refers to bivalent straight or branched chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, *e.g.*, $\{-\text{CH}_2-\}_n$, wherein n is 1 to 12, preferably 1-8. Lower alkylene groups, that is, alkylene groups of 1 to 4 carbon atoms, are most preferred. The terms "alkenylene" and "alkynylene" refer to bivalent radicals of alkenyl and alkynyl groups, respectively, as defined above.

When reference is made to a substituted alkylene, alkenylene, or alkynylene group, these groups are substituted with one to three substituents as defined above for alkyl groups. A ringed substituent of an alkyl, alkenyl, alkynyl, alkylene, alkenylene, or alkynylene may be joined at a terminal atom or an available intermediate (branch or chain) atom and thus may comprise, for example, the groups



The term "alkoxy" refers to an alkyl group as defined above having one, two or three oxygen atoms (-O-) in the alkyl chain. For example, the term "alkoxy" includes the groups $-\text{O}-\text{C}_{1-12}\text{alkyl}$, $-\text{C}_{1-6}\text{alkylene}-\text{O}-\text{C}_{1-6}\text{alkyl}$, $-\text{C}_{1-4}\text{alkylene}-\text{O}-\text{C}_{1-4}\text{alkylene}-\text{O}-\text{C}_{1-4}\text{alkyl}$, $\text{O}-\text{C}_{1-4}\text{alkylene}-\text{O}-\text{C}_{1-4}\text{alkylene}-\text{O}-\text{C}_{1-4}\text{alkyl}$, and so forth.

The term "alkylthio" refers to an alkyl group as defined above bonded through one or more sulfur (-S-) atoms. For example, the term "alkylthio" includes the groups $-\text{S}-\text{C}_{1-12}\text{alkyl}$, $-\text{S}_{1-6}\text{alkylene}-\text{S}-\text{C}_{1-6}\text{alkyl}$, etc.

The term "alkylamino" refers to an alkyl group as defined above bonded through one or more nitrogen (-NR-) groups. The term alkylamino refers to straight and branched

chain groups and thus, for example, includes the groups $\text{-NH}(\text{C}_{1-12}\text{alkyl})$ and $\text{-N}(\text{C}_{1-6}\text{alkyl})_2$.

When a subscript is used with reference to an alkoxy, alkylthio or alkylamino, the subscript refers to the number of carbon atoms in the group in addition to heteroatoms.

5 Thus, for example, monovalent C_{1-2} alkylamino includes the groups -NH-CH_3 , $\text{-NH-CH}_2\text{-CH}_3$, and $\text{-N-(CH}_3)_2$. A lower alkylamino comprises an alkylamino having from one to four carbon atoms.

When reference is made to a substituted alkoxy or alkylthio, the carbon atoms of said groups are substituted with one to three substituents as defined above for alkyl
10 groups. When reference is made to a substituted alkylamino, the carbon and/or nitrogen atoms of these groups are substituted with one to three substituents appropriately selected from the group of substituents recited above for alkyl groups. Additionally, the alkoxy, alkylthio, or alkylamino groups may be monovalent or bivalent. By
15 "monovalent" it is meant that the group has a valency (*i.e.*, power to combine with another group), of one, and by "bivalent" it is meant that the group has a valency of two. Thus, for example, a monovalent alkoxy includes groups such as $\text{-O-C}_{1-12}\text{alkyl}$ and $\text{-C}_{1-6}\text{alkylene-O-C}_{1-6}\text{alkyl}$, whereas a bivalent alkoxy includes groups such as $\text{-O-C}_{1-12}\text{alkylene-}$ and $\text{-C}_{1-6}\text{alkylene-O-C}_{1-6}\text{alkylene-}$, etc.

The term "heteroalkyl" is used herein to refer saturated and unsaturated straight or
20 branched chain hydrocarbon groups having 2 to 12 carbon atoms, preferably 2 to 8 carbon atoms, wherein one, two or three carbon atoms in the straight chain are replaced by a heteroatom (O, S or N). Thus, the term "heteroalkyl" includes alkoxy, alkylthio, and alkylamino groups, as defined above, as well as alkyl groups having a combination of heteroatoms selected from O, S, or N. A "heteroalkyl" herein may be monovalent or
25 bivalent, and for example, may comprise the groups $\text{-O-(CH}_2)_{2-5}\text{NH-(CH}_2)_2\text{-}$ or $\text{-O-(CH}_2)_{2-5}\text{NH-CH}_3$, etc. A "substituted heteroalkyl" has one to three substituents appropriately selected from those recited above for alkyl groups.

The term "acyl" refers to a carbonyl group ($\text{—}\overset{\text{O}}{\underset{\text{||}}{\text{C}}}\text{—}$) linked to an organic radical including an alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, or substituted alkynyl group, as defined above.

The term "alkoxycarbonyl" refers to a carboxy or ester group ($\text{—}\overset{\text{O}}{\underset{\text{||}}{\text{C}}}\text{—O—}$) linked to an organic radical including an alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, or substituted alkynyl group, as defined above.

The term "halo" or "halogen" refers to chloro, bromo, fluoro and iodo.

The term "haloalkyl" means an alkyl having one or more halo substituents, *e.g.*, including trifluoromethyl.

The term "haloalkoxy" means an alkoxy group having one or more halo substituents. For example, "haloalkoxy" includes —OCF_3 .

The term "sulfonyl" refers to a sulfoxide group (*i.e.*, $\text{—S(O)}_{1-2}\text{—}$) linked to an organic radical including an alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, or substituted alkynyl group, as defined above. The organic radical to which the sulfoxide group is attached may be monovalent (*e.g.*, $\text{—SO}_2\text{—alkyl}$), or bivalent (*e.g.*, $\text{—SO}_2\text{—alkylene}$, etc.)

The term "sulfonamide" refers to the group $\text{—S(O)}_2\text{NR'R''}$, wherein R' and R'' may be hydrogen or alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, or substituted alkynyl, as defined above. R' and R'' may be monovalent or bivalent (*e.g.*, $\text{—SO}_2\text{—NH—alkylene}$, etc.)

The term "aryl" refers to phenyl, biphenyl, 1-naphthyl and 2-naphthyl, with phenyl being preferred. The term "aryl" includes such rings having zero, one, two or three substituents selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, hydroxy, alkoxy, alkylthio, $\text{—CO}_2\text{H}$, —C(=O)H , $\text{CO}_2\text{—alkyl}$, —C(=O)alkyl , phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, cycloalkyl, heterocyclo, heteroaryl, —NR'R'' , —C(=O)NR'R'' , $\text{—CO}_2\text{NR'R''}$, $\text{—NR'CO}_2\text{'R''}$, —NR'C(=O)R'' , $\text{—SO}_2\text{NR'R''}$, $\text{—NR'SO}_2\text{'R''}$, and/or alkyl substituted with one to three of halo, nitro, cyano, hydroxy,

alkoxy, alkylthio, $-\text{CO}_2\text{H}$, $-\text{C}(=\text{O})\text{H}$, $\text{CO}_2\text{-alkyl}$, $-\text{C}(=\text{O})\text{alkyl}$, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, cycloalkyl, heterocyclo, heteroaryl, $-\text{NR}'\text{R}''$, $-\text{C}(=\text{O})\text{NR}'\text{R}''$, $-\text{CO}_2\text{NR}'\text{R}''$, $-\text{NR}'\text{CO}_2'\text{R}''$, $-\text{NR}'\text{C}(=\text{O})\text{R}''$, $-\text{SO}_2\text{NR}'\text{R}''$, and/or $-\text{NR}'\text{SO}_2'\text{R}''$, wherein each of R' and R'' is independently selected from hydrogen, alkyl, alkoxy, hydroxyalkyl, and arylalkyl, or R' and R'' together form a heterocyclo or heteroaryl ring. When an aryl is substituted with a further ring, said ring may in turn be substituted with one to three of halogen, haloalkyl, haloalkoxy, cyano, nitro, hydroxy, alkoxy, alkylthio, amino, alkylamino, phenyl, benzyl, phenyloxy, and benzyloxy.

The term "cycloalkyl" refers to fully saturated and partially unsaturated hydrocarbon rings of 3 to 9, preferably 3 to 7 carbon atoms. The term "cycloalkyl" includes such rings having zero, one, two, or three substituents, preferably zero or one, selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, oxo ($=\text{O}$), hydroxy, alkoxy, alkylthio, $-\text{CO}_2\text{H}$, $-\text{C}(=\text{O})\text{H}$, $\text{CO}_2\text{-alkyl}$, $-\text{C}(=\text{O})\text{alkyl}$, keto, $=\text{N-OH}$, $=\text{N-O-alkyl}$, heteroaryl, heterocyclo, a five or six membered ketal (*i.e.* 1,3-dioxolane or 1,3-dioxane), a four to seven membered carbocyclic ring, $-\text{NR}'\text{R}''$, $-\text{C}(=\text{O})\text{NR}'\text{R}''$, $-\text{CO}_2\text{NR}'\text{R}''$, $-\text{NR}'\text{CO}_2'\text{R}''$, $-\text{NR}'\text{C}(=\text{O})\text{R}''$, $-\text{SO}_2\text{NR}'\text{R}''$, $-\text{NR}'\text{SO}_2'\text{R}''$, and/or alkyl substituted with one to three of halo, nitro, cyano, hydroxy, alkoxy, alkylthio, $-\text{CO}_2\text{H}$, $-\text{C}(=\text{O})\text{H}$, $\text{CO}_2\text{-alkyl}$, $-\text{C}(=\text{O})\text{alkyl}$, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, a four to seven membered carbocyclic ring, heterocyclo, heteroaryl, $-\text{NR}'\text{R}''$, $-\text{C}(=\text{O})\text{NR}'\text{R}''$, $-\text{CO}_2\text{NR}'\text{R}''$, $-\text{NR}'\text{CO}_2'\text{R}''$, $-\text{NR}'\text{C}(=\text{O})\text{R}''$, $-\text{SO}_2\text{NR}'\text{R}''$, and/or $-\text{NR}'\text{SO}_2'\text{R}''$, wherein each of R' and R'' is independently selected from hydrogen, alkyl, alkoxy, hydroxyalkyl, and arylalkyl, or R' and R'' together form a heterocyclo or heteroaryl ring. When a cycloalkyl is substituted with a further ring, said ring may in turn be substituted with one to three of halogen, haloalkyl, haloalkoxy, cyano, nitro, hydroxy, alkoxy, alkylthio, amino, alkylamino, phenyl, benzyl, phenyloxy, and benzyloxy.

The term "heterocyclo" refers to substituted and unsubstituted non-aromatic 3 to 7 membered monocyclic groups, 7 to 11 membered bicyclic groups, and 10 to 15 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one

of the rings. Each ring of the heterocyclo group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. The heterocyclo group may be attached at any available nitrogen or carbon atom. The heterocyclo ring may contain zero, one, two or three substituents selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, oxo, hydroxy, alkoxy, alkylthio, -CO₂H, -C(=O)H, CO₂-alkyl, -C(=O)alkyl, keto, =N-OH, =N-O-alkyl, aryl, heteroaryl, cycloalkyl, a five or six membered ketal (*i.e.* 1,3-dioxolane or 1,3-dioxane), -NR'R'', -C(=O)NR'R'', -CO₂NR'R'', -NR'CO₂R'', -NR'C(=O)R'', -SO₂NR'R'', -NR'SO₂R'', and/or alkyl substituted with one to three of halo, nitro, cyano, hydroxy, alkoxy, alkylthio, -CO₂H, -C(=O)H, CO₂-alkyl, -C(=O)alkyl, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, cycloalkyl, heterocyclo, heteroaryl, -NR'R'', -C(=O)NR'R'', -CO₂NR'R'', -NR'CO₂R'', -NR'C(=O)R'', -SO₂NR'R'', and/or -NR'SO₂R'', wherein each of R' and R'' is independently selected from hydrogen, alkyl, alkoxy, hydroxyalkyl, and arylalkyl, or R' and R'' together form a heterocyclo or heteroaryl ring. When a heterocyclo is substituted with a further ring, said ring may in turn be substituted with one to three of halogen, haloalkyl, haloalkoxy, cyano, nitro, hydroxy, alkoxy, alkylthio, amino, alkylamino, phenyl, benzyl, phenyloxy, and benzyloxy.

Exemplary monocyclic groups include azetidiny, pyrrolidiny, oxetany, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidiny, piperaziny, 2-oxopiperaziny, 2-oxopiperidiny, 2-oxopyrrolodiny, 2-oxoazepiny, azepiny, 4-piperidony, tetrahydropyrany, morpholinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl and the like. Exemplary bicyclic heterocyclo groups include quinuclidiny.

The term "heteroaryl" refers to substituted and unsubstituted aromatic 5 or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S or N) in at least one of the rings. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. The heteroaryl ring system may contain zero, one, two or three substituents selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, hydroxy, alkoxy, alkylthio, -CO₂H, -C(=O)H, CO₂-alkyl, -C(=O)alkyl, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, cycloalkyl, heterocyclo, a further monocyclic heteroaryl, -NR'R'', -C(=O)NR'R'', -CO₂NR'R'', -NR'CO₂'R'', -NR'C(=O)R'', -SO₂NR'R'', -NR'SO₂'R'', and/or alkyl substituted with one to three of halo, nitro, cyano, hydroxy, alkoxy, alkylthio, -CO₂H, -C(=O)H, CO₂-alkyl, -C(=O)alkyl, phenyl, benzyl, phenylethyl, phenyloxy, phenylthio, cycloalkyl, heterocyclo, heteroaryl, -NR'R'', -C(=O)NR'R'', -CO₂NR'R'', -NR'CO₂'R'', -NR'C(=O)R'', -SO₂NR'R'', and/or -NR'SO₂'R'', wherein each of R' and R'' is independently selected from hydrogen, alkyl, alkoxy, hydroxyalkyl, and arylalkyl, or R' and R'' together form a heterocyclo or heteroaryl ring. When a heteroaryl is substituted with a further ring, said ring may in turn be substituted with one to three of halogen, haloalkyl, haloalkoxy, cyano, nitro, hydroxy, alkoxy, alkylthio, amino, alkylamino, phenyl, benzyl, phenyloxy, and benzyloxy.

Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.

Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indoliziny, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxaliny, indazolyl, pyrrolopyridyl, furopyridinyl, dihydroisoindolyl, tetrahydroquinolinyl and the like.

Exemplary tricyclic heteroaryl groups include carbazolyl, benzidolyl, phenanthrollinyl, acridinyl, phenanthridinyl, xanthenyl and the like.

The term "carbocyclic" refers to optionally substituted aromatic or non-aromatic 3 to 7 membered monocyclic and 7 to 11 membered bicyclic groups, in which all atoms of the ring or rings are carbon atoms.


When the term "unsaturated" is used herein to refer to a ring or group, the ring or group may be fully unsaturated or partially unsaturated.

The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.


Whenever a bond appears in a formula as a dashed-double bond, i.e., with one bond appearing as a dash as in $\overset{\text{H}_2}{\text{C}} \text{--} \overset{\text{H}_2}{\text{C}}$, it should be understood that such bonds may be selected from single or double bonds, as appropriate given the selections for adjacent atoms and bonds. It should be further understood that one skilled in the field may make various substitutions for each of the groups recited in the claims herein, without departing from the spirit or scope of the invention. For example, one skilled in the field may replace a W group recited in the claims with a cyano, halogen, or methyl group. The linker group "L" recited in the claims may be replaced with the group $-(\text{R}')_u\text{-Y}'\text{-(R'')}_v$ wherein Y' is a Y group recited in claim 1, is a bond, or is selected from $-\text{C}(=\text{O})-$, $-\text{[C}(=\text{O})]_2-$, $-\text{O}-$, $-\text{NR}-$, $-\text{C}(=\text{NR})-$, $-\text{S}(\text{O})_{1-2}-$, $-\text{NRC}(=\text{O})\text{NR}-$, $-\text{NRSO}_2-$, or $-\text{SO}_2\text{NR}-$, wherein R is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, a heterocyclo or carbocyclic ring, and so forth, R' and R'' may comprise substituted or unsubstituted alkylene, alkenylene, or alkynylene, and u and v may be 0-4. Additionally,

the acid group $-\text{CO}_2\text{R}_3$ may be joined to the phenyl or pyridyl ring B with a linker such as a methylene group or replaced with other acid functional groups such as $-\text{SO}_3\text{H}$, $-\text{P}(=\text{O})(\text{OR})_2$, $-\text{SO}_2\text{NHC}(=\text{O})\text{R}$, $-\text{C}(=\text{O})\text{NHSO}_2\text{R}$, $-\text{C}(=\text{O})\text{NHOH}$, $-\text{[C}(=\text{O})]_2\text{OR}$, or tetrazole, wherein R is hydrogen, alkyl, substituted alkyl, cycloalkyl, and so forth.

- 5 Additionally, it should be understood that when a bond is represented as generally being attached to a bicyclic ring system, without indicating the precise point of attachment, the bond may be attached to any available carbon or nitrogen atom of either ring. For example, the ring systems recited as




and




may be attached to a substrate at any

- 10 available carbon atom of either the five membered or six membered rings, and the ring




systems recited as



may be attached to a

substrate at any available carbon atom or nitrogen atom of the five or six membered rings.

- It should be further understood that for compounds of formula I and II, the linker group "L" is inserted into the formula I or II in the same direction set forth in the text. Thus, for example, if L is recited as $-\text{CH}_2-\text{Y}-$, this means the $-\text{CH}_2-$ group is attached to Z, and the Y group is attached to the C_6 carbon atom *i.e.*, to which R_4 is



attached, as in:

Likewise, when Y is recited as $-\text{NR}_{13}\text{C}(=\text{O})-$,

the carbonyl group $\text{C}(=\text{O})$ is attached to the C_6 carbon atom and the nitrogen group

- 20 $-\text{NR}_{13}-$ is attached to Z. Conversely, when Y is recited as $-\text{C}(=\text{O})\text{NR}_{13}-$, this means the carbonyl group $\text{C}(=\text{O})$ is attached to Z and the nitrogen group $-\text{NR}_{13}-$ is attached to the C_6 carbon atom.

Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds.

The compounds of formula I or II form salts which are also within the scope of this invention. Unless otherwise indicated, reference to an inventive compound is understood to include reference to salts thereof. The term "salt(s)" denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, the term "salt(s)" may include zwitterions (inner salts), *e.g.*, when a compound of formula I or II contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid. Pharmaceutically acceptable (*i.e.*, non-toxic, physiologically acceptable) salts are preferred, such as, for example, acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. However, other salts may be useful, *e.g.*, in isolation or purification steps which may be employed during preparation, and thus, are contemplated within the scope of the invention. Salts of the compounds of the formula I or II may be formed, for example, by reacting a compound of the formula I or II with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed with maleic acid), methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotines, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed

with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts with organic bases (for example, organic amines) such as trialkylamines such as triethylamine, procaine, dibenzylamine, N-benzyl- β -phenethylamine, 1-phenamine, N,N'-dibenzylethylene-diamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others. Preferred salts include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate.

Prodrugs and solvates of the inventive compounds are also contemplated. The term "prodrug" denotes a compound which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of the formula I or II, and/or a salt and/or solvate thereof. Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985);
- b) A Textbook of Drug Design and Development, edited by Krosgaard-Larsen and H. Bundgaard, Chapter 5, "Design and Application of Prodrugs," by H. Bundgaard, p. 113-191 (1991); and
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992), each of which is incorporated herein by reference.

Compounds containing a carboxy group can form physiologically hydrolyzable esters which serve as prodrugs by being hydrolyzed in the body to yield formula I or II compounds *per se*. For example, in compounds of formula (I), prodrugs comprise compounds wherein the upper ring substituent $-CO_2R_8$ is a group that will hydrolyze in the body to compounds where said substituent is $-CO_2H$. Such prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration may be used where the ester *per se* is active, or in those instances where hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of formula I or II include C_{1-6} alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C_{1-6} alkanoyloxy- C_{1-6} alkyl, *e.g.* acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl, C_{1-6} alkoxycarbonyloxy- C_{1-6} alkyl, *e.g.* methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters may be prepared by conventional techniques known in the art.


Compounds of the formula I or II and salts thereof may exist in their tautomeric form, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that the all tautomeric forms, insofar as they may exist, are included within the invention. Additionally, inventive compounds may have *trans* and *cis* isomers and may contain one or more chiral centers, therefore existing in enantiomeric and diastereomeric forms. The invention includes all such isomers, as well as mixtures of *cis* and *trans* isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers). When no specific mention is made of the configuration (*cis*, *trans* or R or S) of a compound (or of an asymmetric carbon), then any one of the isomers or a mixture of more than one isomer is intended. The processes for preparation can use racemates, enantiomers or diastereomers as starting materials. When enantiomeric or

diastereomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.

The compounds of the instant invention may, for example, be in the free or hydrate form, and may be obtained by methods exemplified by the following descriptions.

Preferred Compounds

Preferred compounds of this invention are those of formula (I) or (II):



- 10 and pharmaceutically-acceptable salts, hydrates or prodrugs thereof, in which:
 ring B is phenyl;
 W is $-C(=O)NR_9R_{10}$;
 L is $-C(=O)-$, $-(CH_2)_sNHC(=O)-$, $-(CH_2)_sNH-CH_2-$, or $-CH_2-CH_2-$,
 Z_1 is selected from a 5 to 7-membered monocyclic or 8 to 11-membered bicyclic aryl,
 15 heteroaryl, heterocyclo, or cycloalkyl;
 Z_2 is a fully saturated carbocyclic or heterocyclic 5 to 7 membered ring;
 R_1 and R_2 (i) are independently hydrogen, alkyl, arylalkyl or aryl; or (ii) are taken together form a five-to-seven membered aryl, heteroaryl, heterocyclo, cycloalkyl, or substituted cycloalkyl optionally substituted with oxo ($=O$) or one to two R_{26} ;
 20 R_3 and R_4 (i) are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroaryl, aryl, heterocyclo, and cycloalkyl; or (ii) are taken together to form a five-to-seven membered aryl, heteroaryl, cycloalkyl, or heterocyclo, wherein when R_3 and R_4 individually or together form a heteroaryl, aryl,

heterocyclo, or cycloalkyl, said cyclic group is optionally substituted with up to two R_{26} ;

R_5 and R_6 are hydrogen;

R_7 is selected from hydrogen, halogen, $-C(=O)NH_2$, $-C(=O)C_{1-4}alkyl$, $-NH_2$, $-NHC_{1-4}alkyl$, $-S-C_{1-4}alkyl$, $-O-C_{1-4}alkyl$, $C_{1-4}alkyl$, $C_{1-4}alkyl$ substituted with NH_2 , and five

or six membered heterocyclo or heteroaryl;

R_8 is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocyclo, cycloalkyl, or alkyl substituted with $-OC(=O)R_{24}$ or $-OC(=O)O-R_{24}$, wherein R_{24} is alkyl, substituted alkyl, or cycloalkyl, provided that R_8 is not phenyl when W is methoxy;

R_9 and R_{10} are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cyano; or alternatively (ii) R_9 and R_{10} may be taken together to form a five-to-seven membered heteroaryl or heterocyclo;

R_{26} and R_{27} are at each occurrence independently selected from hydrogen, OR_{30} ,

$NR_{31}R_{32}$, alkyl, alkenyl, substituted alkyl, substituted alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, alkylthio, $-C(=O)H$, acyl, $-CO_2H$, alkoxycarbonyl, sulfonamido, sulfonyl, and phenyl;

R_{30} at each occurrence is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, and phenyl;

R_{31} and R_{32} at each occurrence are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, and cycloalkyl; and

s is 0 or 1.


More preferred are compounds as immediately defined above, or pharmaceutically-acceptable salts, hydrates or prodrugs thereof, in which:

W is $-C(=O)NCH(R_{25})-t-butyl$ or $-CH_2C(=O)NCH(R_{25})-t-butyl$;

L is $-NHC(=O)-$; and

R_{25} is hydrogen or CH_2OH .

Further preferred compounds are those having one of the following formulae



in which


- R_1 and R_2 (i) are independently hydrogen, lower alkyl, arylalkyl or aryl; or (ii) are taken together form a five-to-seven membered aryl or heterocyclo optionally substituted with oxo (=O) or one to two R_{26} ;
- R_3 and R_4 (i) are independently selected from hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, heteroaryl, aryl, heterocyclo, and cycloalkyl; or (ii) are taken together to form a five-to-seven membered aryl, heteroaryl, cycloalkyl, or heterocyclo, wherein when R_3 and R_4 individually or together form a heteroaryl, aryl, heterocyclo, or cycloalkyl, said cyclic group is optionally substituted with up to two R_{26} ;
- R_7 is selected from hydrogen, halogen, $-C(=O)NH_2$, $-C(=O)C_{1-4}alkyl$, $-NH_2$, $-NHC_{1-4}alkyl$, $-SC_{1-4}alkyl$, $-OC_{1-4}alkyl$, $C_{1-4}alkyl$, $C_{1-4}alkyl$ substituted with NH_2 , and five or six membered heterocyclo or heteroaryl (most preferably hydrogen);

- R₂₅ is hydrogen or CH₂OH;
R₂₆ is hydrogen, OR₃₀, or NR₃₁R₃₂;
R₃₀ is hydrogen, lower alkyl, C₂₋₄alkenyl, cycloalkyl, phenyl or benzyl; and
R₃₁ and R₃₂ at each occurrence are independently selected from hydrogen, lower alkyl,
5 alkenyl, and cycloalkyl.

Methods of Preparation


- The compounds of the invention may be prepared by the exemplary processes described in the following reaction schemes. Exemplary reagents and procedures for
10 these reactions appear hereinafter and in the working Examples. Starting materials are commercially available or can be readily prepared by one of ordinary skill in the art. For all of the schemes, the groups R₁-R₂₇, W, Z, *s* and *r* are as described herein for a compound of formula I or II, unless otherwise indicated. Groups designated R', P', and P'' as well as solvents, temperatures, pressures, and other reaction conditions, may readily
15 be selected as appropriate by one of ordinary skill in the art. Additionally, one skilled in the field will appreciate that it may be advantageous in the following schemes to attach further protecting groups to the functional groups of starting materials or intermediates which then may be removed using appropriate deprotecting conditions. *See*, for example, Greene and Wuts, Protecting Groups in Organic Synthesis (John Wiley & Sons, New
20 York 1991), incorporated herein by reference.

SCHEME A




- Compounds of formula IIa can be made by reacting acid **1**, prepared with known methods, with an amidine having the desired Z group, *i.e.*, $\text{NHR}_6\text{C}(=\text{NR}_5)\text{-Z-}(\text{CR}_{18}\text{R}_{19})_5\text{-NHR}_{13}$. The 2-position acid group is suitably protected (P'), and the reaction is carried out in the presence of coupling reagent(s) such as DCC/HOBT/DMAP, EDC/DMAP, or DIC/HOAT to afford the corresponding amide compound. Deprotection, if desired, then affords the compound of formula IIa wherein R_8 is hydrogen, or the group P' may be retained wherein P' comprises the desired group R_3 .
- Alternatively, the group P' may be deprotected to afford the group CO_2H , with the group CO_2H then converted to another desired R_3 group. To illustrate, the compound having the acid group CO_2H may be reacted with a halide having the desired R_3 group, *i.e.*, X-R_3 where X is Cl, Br, or I, in the presence of base, or by the acid compound may be coupled with an alcohol such as R_3OH in a coupling reagent. Compound **1** can be prepared as described in WO 99/041231, incorporated herein.

SCHEME B




Similar to Scheme A, reaction of aldehyde 2, prepared by known methods, wherein the 2-position acid group is suitably protected (P'), with an amidine $\text{NHR}_6\text{C}(=\text{NR}_7)\text{-Z-(CR}_{18}\text{R}_{19})_s\text{-NHR}_{13}$ in the presence of a reducing reagent such as sodium triacetoxyborohydride, affords the corresponding amide compound. Upon optional deprotection or further reaction or coupling as described in Scheme A, the compound of formula IIb having the desired R_8 group is provided. Compound 2 can be prepared as described in WO 99/041231.



Aryl fluoride **3a** is reacted with amine **4** in DMSO in the presence of a base
 5 such as DIEA to afford intermediate **5**. Alternatively, triflate **3b** is reacted with amine **4**
 in the presence of a suitable palladium reagent to afford intermediate **5**. Selective
 deprotection of the P'' group of compound **5** affords acid **6**. Acid **6** is reacted with an
 appropriate amidine $\text{NHR}_6\text{C}(=\text{NR}_7)\text{-Z-(CR}_{18}\text{R}_{19})_s\text{-NHR}_{13}$ in the presence of suitable
 coupling reagents followed by deprotection, if desired to achieve the selected group R_8
 10 (as described in Scheme A) to afford the compound of formula **Ib**.

SCHEME D



Aryl fluoride **3a** is reacted with amine **7** in DMSO in the presence of a base such as DIEA to afford compound **8**, where R_3 is defined as above except where R_3 and R_4 form a ring, said ring is a heterocycle. Selective deprotection of the P'' group affords acid **9**. Reaction of acid **9** with an amidine $NHR_6C(=NR_7)-Z-(CR_{18}R_{19})_s-NHR_{13}$ in the presence of coupling reagent(s) such as DCC/HOBT/DMAP, EDC/DMAP, or DIC/HOAT affords the corresponding amidine compound which upon further optional deprotection, coupling or reaction (as described in Scheme A) affords the compound of formula **1c**, having the desired group R_8 . Further schemes for making Z group coupling components are described in US patent application Serial No. _____, being filed concomitantly herewith, having common inventors herein and assigned to the present assignee, which is incorporated herein by reference.

Utility

The inventive compounds are inhibitors of the activated coagulation serine proteases known as Factor VIIa, Factor IXa, Factor Xa, Factor XIa, and thrombin and also inhibit other serine proteases, such as trypsin, tryptase, and urokinase. Thus, the compounds are useful for treating or preventing those processes, which involve the production or action of Factor VIIa, Factor IXa, Factor Xa, Factor XIa, thrombin, trypsin,

and/or tryptase. In view of their urokinase inhibitory activity, they are useful as metastasis inhibitors in treating cancer. As used herein with reference to the utilities described below, the term "treating" or "treatment" encompasses prevention, partial alleviation, or cure of the disease or disorder.

5 In view of their above-referenced serine protease inhibitory activity, the inventive compounds are useful in treating consequences of atherosclerotic plaque rupture including cardiovascular diseases associated with the activation of the coagulation cascade in thrombotic or thrombophilic states. Such diseases include arterial thrombosis, coronary artery disease, acute coronary syndromes, myocardial infarction,
10 unstable angina, ischemia resulting from vascular occlusion cerebral infarction, stroke and related cerebral vascular diseases (including cerebrovascular accident and transient ischemic attack). Additionally, the compounds are useful in treating or preventing formation of atherosclerotic plaques, transplant atherosclerosis, peripheral arterial disease and intermittent claudication. In addition, the compounds can be used to prevent
15 restenosis following arterial injury induced endogenously (by rupture of an atherosclerotic plaque), or exogenously (by invasive cardiological procedures such as vessel wall injury resulting from angioplasty).

 In addition, the inventive compounds are useful in preventing venous thrombosis, coagulation syndromes, deep vein thrombosis (DVT), disseminated
20 intravascular coagulopathy, Kasabach-Merritt syndrome, pulmonary embolism, cerebral thrombosis, atrial fibrillation, and cerebral embolism. The compounds are useful in treating peripheral arterial occlusion, thromboembolic complications of surgery (such as hip replacement, endarterectomy, introduction of artificial heart valves, vascular grafts, and mechanical organs), implantation or transplantation of organ, tissue or cells, and
25 thromboembolic complications of medications (such as oral contraceptives, hormone replacement, and heparin, *e.g.*, for treating heparin-induced thrombocytopenia). The inventive compounds are useful in preventing thrombosis associated with artificial heart valves, stents, and ventricular enlargement including dilated cardiac myopathy and heart

failure. The compounds are also useful in treating thrombosis due to confinement (*i.e.* immobilization, hospitalization, bed rest etc.).

These compounds are also useful in preventing thrombosis and complications in patients genetically predisposed to arterial thrombosis or venous thrombosis (including
5 activated protein C resistance, FV_{leiden}, Prothrombin 20210, elevated coagulation factors FVII, FVIII, FIX, FX, FXI, prothrombin, TAFI and fibrinogen), elevated levels of homocystine, and deficient levels of antithrombin, protein C, and protein S. The inventive compounds may be used for treating heparin-intolerant patients, including those with congenital and acquired antithrombin III deficiencies, heparin-induced
10 thrombocytopenia, and those with high levels of polymorphonuclear granulocyte elastase.

The present compounds may also be used to inhibit blood coagulation in connection with the preparation, storage, fractionation, or use of whole blood. For example, the compounds may be used to maintain whole and fractionated blood in the fluid phase such as required for analytical and biological testing, *e.g.*, for *ex vivo* platelet
15 and other cell function studies, bioanalytical procedures, and quantitation of blood-containing components. The compounds may be used as anticoagulants in extracorporeal blood circuits, such as those necessary in dialysis and surgery (such as coronary artery bypass surgery); for maintaining blood vessel patency in patients undergoing transluminal coronary angioplasty, vascular surgery including bypass grafting, arterial
20 reconstruction, atherectomy, vascular graft and stent patency, tumor cell metastasis, and organ, tissue, or cell implantation and transplantation.

In view of their tryptase inhibitory activity, the inventive compounds are useful as anti-inflammatory agents, in treating chronic asthma, allergic rhinitis, inflammatory bowel disease, psoriasis, conjunctivitis, atopic dermatitis, pancreatitis, rheumatoid arthritis,
25 osteoarthritis, septic shock, and chronic inflammatory joint diseases, diseases of joint cartilage destruction, and/or vascular damage due to bacterial and/or viral infections. Additionally, the inventive compounds may be useful for treating diabetic retinopathy or motor neuron diseases such as amyotrophic lateral sclerosis, progressive muscular

atrophy, and primary lateral sclerosis. Additionally, the inventive compounds may be useful for tissue remodeling diseases and for treating plaque instability and sequeli. In addition, these compounds may be useful for treating fibrotic diseases and conditions, for example, fibrosis, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, 5 neurofibromas, and hypertrophic scars.

In addition, the compounds of the present invention are useful in treating cancer and preventing the prothrombotic complications of cancer. In view of their metastasis inhibition activity, the compounds are useful in treating tumor growth, as an adjunct to chemotherapy, and for treating diseases involving metastases including, but not limited to 10 cancer, more particularly, cancer of the lung, prostate, colon, breast, ovaries, and bone. These compounds may also be useful in preventing angiogenesis.

The inventive compounds may also be used in combination with other antithrombotic or anticoagulant drugs such as thrombin inhibitors, platelet aggregation inhibitors such as aspirin, clopidogrel, ticlopidine or CS-747, warfarin, low molecular 15 weight heparins (such as LOVENOX), GPIIb/GPIIIa blockers, PAI-1 inhibitors such as XR-330 and T-686, inhibitors of α -2-antiplasmin such as anti- α -2-antiplasmin antibody and thromboxane receptor antagonists (such as ifetroban), prostacyclin mimetics, phosphodiesterase (PDE) inhibitors, such as dipyridamole or cilostazol, PDE inhibitors in combination with thromboxane receptor antagonists/thromboxane A synthetase inhibitors 20 (such as picotamide), serotonin-2-receptor antagonists (such as ketanserin), fibrinogen receptor antagonists, hypolipidemic agents, such as HMG-CoA reductase inhibitors, *e.g.*, pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, itavastatin (Nissan/Kowa), and compounds disclosed in U.S. provisional applications No. 60/211,594 filed June 15, 2000, and No. 60/211,595 filed June 15, 2000; microsomal 25 triglyceride transport protein inhibitors (such as disclosed in U.S. Patent Nos. 5,739,135, 5,712,279 and 5,760,246), antihypertensive agents such as angiotensin-converting enzyme inhibitors (*e.g.*, captopril, lisinopril or fosinopril); angiotensin-II receptor antagonists (*e.g.*, irbesartan, losartan or valsartan); and/or ACE/NEP inhibitors (*e.g.*,

omapatrilat and gemopatriat); β -blockers (such as propranolol, nadolol and carvedilol), PDE inhibitors in combination with aspirin, ifetroban, picotamide, ketanserin, or clopidogrel and the like. The inventive compounds are also useful in combination with anti-arrhythmic agents such as for atrial fibrillation, for example, amiodarone or
5 dofetilide.

The inventive compounds may be used in combination with prothrombolytic agents, such as tissue plasminogen activator (natural or recombinant), streptokinase, reteplase, activase, lanoteplase, urokinase, prourokinase, anisolated streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators,
10 and the like.

The inventive compounds may also be used in combination with β -adrenergic agonists such as albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, or fenoterol; anticholinergics such as ipratropium bromide; anti-inflammatory corticosteroids such as beclomethasone, triamcinolone, budesonide, fluticasone,
15 flunisolide or dexamethasone; and anti-inflammatory agents such as cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast and pranleukast.

The inventive compounds may also be useful in combination with other anticancer strategies and chemotherapies such as taxol and/or cisplatin.

The compounds may act synergistically with one or more of the above agents.
20 For example, the inventive compounds may act synergistically with the above agents to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. Thus, reduced doses of thrombolytic agent(s) may be used, therefore minimizing potential hemorrhagic side effects.

The compounds of formula I or II may be administered by any means suitable
25 for the condition to be treated, which may depend on the need for site-specific treatment or quantity of drug to be delivered. Systematic treatment is typically preferred for cancerous conditions, although other modes of delivery are contemplated. The compounds may be delivered orally, such as in the form of tablets, capsules, granules,

powders, or liquid formulations including syrups; sublingually; buccally; transdermally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion (*e.g.*, as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; rectally such as in the form of suppositories; or
5 liposomally. Dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents may be administered. The compounds may be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved with suitable pharmaceutical compositions or, particularly in the case of extended release, with devices such as subcutaneous
10 implants or osmotic pumps.

Exemplary compositions for oral administration include suspensions which may contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release
15 tablets which may contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The inventive compounds may be orally delivered by sublingual and/or buccal administration, *e.g.*, with molded, compressed, or freeze-dried tablets. Exemplary compositions may include fast-
20 dissolving diluents such as mannitol, lactose, sucrose, and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (AVICEL®) or polyethylene glycols (PEG); an excipient to aid mucosal adhesion such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (SCMC), and/or maleic anhydride copolymer (*e.g.*,
25 GANTREZ®); and agents to control release such as polyacrylic copolymer (*e.g.*, CARBOPOL 934®). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

Exemplary compositions for nasal aerosol or inhalation administration include solutions which may contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance absorption and/or bioavailability, and/or other solubilizing or dispersing agents such as those known in the art.

5 Exemplary compositions for parenteral administration include injectable solutions or suspensions which may contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including
10 oleic acid.

Exemplary compositions for rectal administration include suppositories which may contain, for example, suitable non-irritating excipients, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures but liquefy and/or dissolve in the rectal cavity to release the drug.

15 The effective amount of a compound of the present invention may be determined by one of ordinary skill in the art. The specific dose level and frequency of dosage for any particular subject may vary and will depend upon a variety of factors, including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the species, age, body weight, general health, sex and diet of the
20 subject, the mode and time of administration, rate of excretion, drug combination, and severity of the particular condition. An exemplary effective amount of compounds of formula I or II may be within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) on a regimen in
25 single or 2 to 4 divided daily doses.

Enzyme Assays

Compound was prepared as a 5 mM stock in DMSO, diluted further in DMSO and added directly to the assays. The DMSO concentration for all these studies was less than 1% and compared to DMSO vehicle controls.

Human Factor VIIa was obtained from Enzyme Research Labs (Cat.# HFVIIA 1640). Human recombinant tissue factor (INNOVIN from Dade Behring Cat.# B4212-100; "20 ml vial") was diluted with 8 ml of H₂O per vial and diluted further 1:30 into the 302 µl final assay volume. Tissue factor activated FVIIa enzymatic activity was measured in a buffer containing 150 mM NaCl, 5mM CaCl₂, 1 mM CHAPS and 1 mg/ml PEG 6000 (pH 7.4) with 1 nM FVIIa and 100 µM D-Ile-Pro-Arg-AFC (Enzyme Systems Products, K_m > 200 µM) 0.66% DMSO. The assay (302 µl total volume) was incubated at RT for 2 hr prior to reading fluorometric signal (Ex 405 / Em 535) using a Victor 2 (Wallac) fluorescent plate reader.

Human Factor IXa (American Diagnostica # 449b) enzymatic activity was measured in a buffer containing 50 mM Tris, 100 mM CaCl₂, 5 mM CaCl₂, 33% ethylene glycol at pH 7.5 using 96-well microtiter plates (Nunc # 439454). The enzyme was incubated with the inhibitor at RT for three minutes prior to starting the reaction with 500 uM Spectrozyme FIXa (American Diagnostica #299). The K_m for this substrate is estimated by American Diagnostica to be 1.3 mM. Time dependent optical density change was followed at 405 nm using a kinetic microplate read (Molecular Devices Spectramax Plus) at RT. Enzyme activity in the presence of inhibitor was expressed as fraction of a DMSO-containing control and curve fit to the equation: activity = control activity/(1+[I]/IC₅₀) using Excel Fit.

Human FXa (Calbiochem #233526) enzymatic activity was measured in a buffer containing 0.145 M NaCl, 0.005 M KCl, 1 mg/ml Polyethylene Glycol (PEG-8000), 0.030 M HEPES (pH 7.4) using 96-well microtiter plates (Nunc Immuno #439454). The enzyme was incubated with the inhibitor at RT for three minutes prior to starting the reaction with 100 µM S-2222 (phenyl-Ile-Glu-Gly-Arg-pNA, K_m = 137 µM). The K_m for this and other substrates was determined experimentally by measuring the enzyme

activity at different substrate concentrations and curve fitting the data using Kaleidagraph V. Time-dependent optical density change was followed at 405 nm using a kinetic microplate reader (Molecular Devices UV_{max}) at RT. Enzyme activity in the presence of inhibitor was expressed as fraction of a DMSO-containing control and curve fit to the equation: activity = control activity/(1 + [I]/IC₅₀) using Excel Fit.

Recombinant urokinase (Abbott Labs, Abbokinase) was assayed in the same buffer as FXa, but the reactions were started with 100 μ M S-2444 (L-pyroGlu-Gly-Arg-pNA, K_m = 31 μ M). Human α -thrombin (Sigma) was measured as for FXa except that the reaction was started with 10 μ M S-2238 (D-Phe-Pip-Arg-pNA, K_m = 2.54 μ M).

Human FXIa assay (Enzyme Research Labs) was measured as for FXa except that the reaction was started with 100 μ M S-2366 (L-pyroGlu-Pro-Arg-pNA, K_m = 86 μ M).

Bovine and human pancreatic trypsin (Sigma) were assayed in 2 mM CaCl₂, 50 mM Tris/Cl (pH 8.0) and the reaction was started with 100 μ M Chromozym-TRY (Carboxybenzoxymethyl-Val-Gly-Arg-pNA, K_m = 46 μ M).

Trypsin inhibition activity was measured using either isolated human skin trypsin or recombinant human trypsin prepared from the human recombinant beta-protrypsin expressed by baculovirus in insect cells. The expressed beta-protrypsin was purified using sequential immobilized heparin affinity resin followed by an immunoaffinity column using an anti-trypsin monoclonal antibody. The protrypsin was activated by auto-catalytic removal of the N-terminal in the presence of dextran sulfate followed by dipeptidyl peptidase I (DPPI) removal of the two N-terminal amino acids to give the mature active enzyme (Sakai *et al*, *J. Clin. Invest.*, Vol. 97 (1996), at pp. 988-995). Essentially equivalent results were obtained using isolated native enzyme or the activated expressed enzyme. The trypsin enzyme was maintained in 2M sodium chloride, 10 mM 4-morpholine-propanesulfonic acid, pH 6.8. The assay procedure employed a 96 well microplate. To each well of the microplate (Nunc MaxiSorp), 250 μ l of assay buffer [containing low molecular weight heparin and tris (hydroxymethyl)aminomethane] was added followed by 2.0 μ l of the test compound in

dimethylsulfoxide. The substrate (10 μ l) was then added to each well to give a final concentration of 100 μ M benzyloxycarbonyl-glycine-proline-arginine-*p*-nitroaniline (CBz-Gly-Pro-Arg-pNA). The microplate was then shaken on a platform vortex mixer at a setting of 800 (Sarstedt TPM-2). After a total of three minutes incubation, 10 μ l of the working stock solution of tryptase was added to each well. The microplate was vortexed again for one minute and then incubated without shaking at RT for an additional 2 minutes. After this time the microplate was read on a microplate reader (Molecular Devices UV max) in the kinetic mode (405 nm wavelength) over twenty minutes at RT. To determine the compound concentration that inhibited half of the enzyme activity (IC₅₀), the fraction of control activity (FCA) was plotted as a function of the inhibitor concentration and curve to fit FCA/(1+[I]/IC₅₀). The IC₅₀ for each compound was determined 2-4 times and the obtained values were averaged.

Applying the above-described assays, the inventive compounds demonstrated activity as inhibitors of Factor VIIa, IXa, Xa, XIa, tryptase and/or urokinase.

The following Examples illustrate embodiments of the inventive compounds and starting materials, and are not intended to limit the scope of the claims. For ease of reference, the following abbreviations are used herein:


Abbreviations

- Me = methyl
- Et = ethyl
- Ph = phenyl
- Bn = benzyl
- t-Bu = tertiary butyl
- Boc = tert-butoxycarbonyl
- CBZ = carbobenzyloxy or carbobenzoxy or benzyloxycarbonyl
- THF = tetrahydrofuran
- EtOAc = ethyl acetate
- DMF = dimethyl formamide
- i-PrOH = isopropanol
- DMSO = dimethyl sulfoxide
- DME = 1,2 dimethoxyethane

- DCE = 1,2 dichloroethane
AcOH = acetic acid
TFA = trifluoroacetic acid
i-Pr₂NEt = diisopropylethylamine
5 DMAP = 4-dimethylaminopyridine
NMM = N-methyl morpholine
NaBH(OAc)₃ = sodium triacetoxymethylborohydride
DCM = 4-(dicyanomethylene)-2-methyl-6-(4-dimethylamino-
styryl)-4H-pyran
10 Pd/C = palladium on carbon
EDC (or EDC.HCl) or EDCI (or EDCI.HCl) or EDAC = 3-ethyl-3'-
(dimethylamino)propyl- carbodiimide hydrochloride (or 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride)
HOBT or HOBT.H₂O = 1-hydroxybenzotriazole hydrate
15 HOAT = 1-Hydroxy-7-azabenzotriazole
Pd(OAc)₂ = Palladium acetate
BINAP = 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
CBZ-Cl = benzyl chloroformate
SAX = Strong Anion Exchanger
20 SCX = Strong Cation Exchanger
PVP = polyvinylpyridine
DCC = dicyclohexylcarbodiimide
DIC = diisopropylcarbodiimide
DMA = dimethyl acetamide
25 DIEA = diisopropylethylamine
DIPEA = diisopropylethylamine
DPPF = 1,1'-bis(diphenylphosphino)ferrocene
TEA = triethylamine
TBS = t-butyltrimethylsilyl
30 Tf = trifluoromethanesulfonyl
L = liter
mL = milliliter
μL = microliter
g = gram(s)
35 mg = milligram(s)
meq = milliequivalent
RT = room temperature
sat or sat'd = saturated
TLC = thin layer chromatography


HPLC = high performance liquid chromatography
 LC/MS = high performance liquid chromatography/mass spectrometry
 MS or Mass Spec = mass spectrometry
 mp = melting point


5

EXAMPLE 1

The compound of Example 1 was prepared following Steps A-D:

10 A.




To a solution of  (100 mg, 0.162 mmol) in toluene (1.5 ml)

under nitrogen were added L-proline t-butylester (40 mg, 0.234 mmol), Pd(OAc)₂ (2.3 mg), R-(+)-BINAP (9.6 mg) and lastly Cs₂CO₃ (83 mg). The reaction mixture was heated at 90°C for 66 hours. The reaction was diluted with methylene chloride:hexane


(1:1, 8 ml) and loaded onto a silica gel cartridge (2 g). Flash chromatography with 0 to 15% EtOAc/hexane provided the above product (57 mg, 0.089 mmol) in 55% yield.

B.




5 The product of Step A (57 mg, 0.089 mmol) was treated with 50% TFA/CH₂Cl₂ under nitrogen for 2 hours. Removal of solvents and drying under vacuum provided the desired hydroxy acid compound. This product also contained a side product wherein the hydroxymethyl group is trifluoroacetylated.

C.



The combined products of Step B were dissolved in DMF:pyridine (1:1, 3 ml) under nitrogen and treated with DCC (36.7mg, 0.178 mmol) and 4-aminobenzamidine.2HCl (74 mg, 0.356 mmol). The reaction mixture was heated to 50°C for 2 hours. Solvents were removed under vacuum with warming to 40°C. Purification by preparative HPLC gave after removal of solvents the desired product (13 mg) and a side product wherein the hydroxymethyl group is trifluoroacetylated (7 mg).


D.



The combined products of Step C (20 mg) were dissolved in methanol (4 ml) and treated with hydrogen (1 atm, balloon) in the presence of 10%Pd/C (50 mg) for 30 minutes. NH_4OH (1.5 ml) was added to the reaction mixture, and the reaction mixture was filtered through a celite pad. Solvents were removed to provide the product of Example 1 (9.8 mg, MS: m/z 496 ($\text{M}+\text{H}^+$)) as a white solid.

EXAMPLES 2 and 3

10










Examples 2 and 3 having formula (If) wherein R_{26} is hydrogen (Example 2) and oxo ($=\text{O}$) (Example 3) were prepared in a similar manner as described above for Example 1.

15

EXAMPLES 3-8


Examples 3 through 8 are prepared in the same or similar manner as described above for Example 1 and in Schemes A-D.

| Example | Structure |
|---------|--|
| 3 |  (Chiral) |
| 4 |  (Chiral) |
| 5 |  |
| 6 |  |
| 7 |  |

**EXAMPLE 9**


5

Step A:



10

(9A)



75 mg (0.19mmol) of Acid, , 54 mg (0.28 mmol) EDAC, 4 mg (0.028 mmol) HOAT, and 3.5 mg (0.028 mmol) 4-DMAP were dissolved in 3 mL DCM and stirred at rt for ½ h. 57 mg (0.28 mmol) 4-amino-piperidine-1-carboxylic acid tert-butyl ester was dissolved in 1 mL N,N-DMF and added to the activated acid solution.

- 5 The reaction stirred at rt overnight. MS, m/z $(M+1)^+ = 583$. 2 mL of TFA was added and the reaction was stirred for 3h. MS, m/z $(M+1)^+ = 483$. The reaction was concentrated via speed vacuum and purified on prep HPLC to give 100 mg (92%) of the compound 9A.

10

Step B: Example 9

15 mg (0.031 mmol) of compound 9A and 8.5mg (0.058 mmol) of 1H-pyrazole-1-carboxamide hydrochloride were dissolved in 2 mL N,N-DMF and placed in an ice bath. 0.02 mL (0.093 mmol) DIPEA was added. The reaction was stirred at rt overnight.


- 15 MS, m/z $(M+1)^+ = 525$. 2 mL 2M KOH in MeOH/H₂O was added to the reaction which was stirred at rt for 3h. The reaction was concentrated on the speed vacuum and purified by prep HPLC to give 0.6 mg (4%) of Example 9 above. MS, m/z $(M+1)^+ = 511$.

20

CLAIMS

We claim:

1. A compound having the formula (I) or (II),



or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which:

ring B is phenyl or pyridyl;


W is selected from C₂₋₁₀alkyl, C₂₋₁₀alkenyl, substituted C₂₋₁₀alkyl, substituted C₂₋10alkenyl, -C(=O)NR₉R₁₀, -OR₉, -CO₂R₉, -C(=O)R₉, -SR₉, -S(O)_pR₉, -NR₉R₁₀,10 -NR₉SO₂R₁₀, -NR₉CO₂R₁₀, -NR₉C(=O)R₁₀, -SO₂NR₉R₁₀, -NR_{9a}SO₂NR₄R₅,-NR_{9a}C(=O)NR₄R₅, heterocyclo, heteroaryl, aryl, and cycloalkyl;Z₁ is selected from a 5 to 7-membered monocyclic or 8 to 11-membered bicyclic aryl, heteroaryl, heterocyclo, or cycloalkyl;15 Z₂ is a fully saturated carbocyclic or heterocyclic 5-7 membered monocyclic or 7-11 membered bicyclic ring;L is -(CR₁₈R₁₉)_s-Y-(CR_{18a}R_{19a})_t-;Y is selected from -C(=O), -C(=O)NR₁₃-, -NR₁₃C(=O)-, -NR₁₃CR₁₄R₁₅-, -CR₁₄R₁₅-NR₁₃-, and -CR₁₃R₁₄-CR₁₅R₁₆-;

20 R₁ and R₂ (i) are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl, heterocyclo, or cycloalkyl; or (ii) are taken together to form a five-to-seven membered fully saturated heterocyclo optionally substituted with one to two R₂₆;

- R_3 and R_4 (i) are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroaryl, aryl, heterocyclo, and cycloalkyl; or (ii) are taken together to form an aryl, heteroaryl, cycloalkyl, or heterocyclo, wherein when R_3 and R_4 individually or together form a heteroaryl, aryl, heterocyclo, or cycloalkyl, said cyclic group is optionally substituted with up to two R_{26} ;
- R_5 and R_6 are independently selected from hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, $-C(=O)H$, acyl, $-CO_2H$, and alkoxycarbonyl, provided that at least one of R_5 and R_6 is hydrogen;
- R_7 is attached to any available carbon or nitrogen atom of Z and is selected from hydrogen, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, $-C(=O)H$, acyl, $-CO_2H$, alkoxycarbonyl, sulfonyl, sulfonamido, aryl, heteroaryl, heterocyclo, or cycloalkyl, except when Z is phenyl, W is OCH_3 , s is 0 and Y is $-CH_2-CH_2-$, then R_7 is not phenyloxy;
- R_8 is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocyclo, cycloalkyl, or alkyl substituted with $-OC(=O)R_{24}$ or $-OC(=O)O-R_{24}$, wherein R_{24} is alkyl, substituted alkyl, or cycloalkyl, provided that R_8 is not phenyl when W is methoxy;
- R_9 , R_{9a} , and R_{10} are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, aryl, heteroaryl, heterocyclo, and cycloalkyl; or alternatively (ii) R_9 and R_{10} may be taken together to form a five-to-seven membered heteroaryl or heterocyclo, except when W is $-S(O)_pR_9$, then R_9 is not hydrogen;
- R_{13} , R_{14} , R_{15} , R_{16} , R_{18} , R_{18a} , R_{19} , and R_{19a} are selected from hydrogen, lower alkyl, hydroxy, or lower alkyl substituted with hydroxy or halogen;
- R_{26} and R_{27} (i) are at each occurrence independently selected from hydrogen, OR_{30} , $NR_{31}R_{32}$, $NR_{31}SO_2R_{32a}$, alkyl, alkenyl, substituted alkyl, substituted alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, alkylthio, $-C(=O)H$, acyl, $-CO_2H$, alkoxycarbonyl, sulfonamido, sulfonyl, and phenyl, or (ii) two of R_{26} and/or two of R_{27} may be taken together to form a fused benzo ring, a fused heteroaryl, a fused

- cycloalkyl, or a fused heterocycle other than a five or six membered heterocycle having as its heteroatoms two oxygen atoms;
- R₃₀ at each occurrence is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, and phenyl;
- 5 R₃₁ and R₃₂ at each occurrence are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, and cycloalkyl;
- R_{32a} is alkyl, substituted alkyl, alkenyl, substituted alkenyl, or cycloalkyl;
- m is 0, 1 or 2 when ring B is phenyl and 0 or 1 when ring B is pyridyl;
- p and q are independently 1 or 2; and
- 10 s and t are independently 0, 1 or 2.
2. The compound of claim 1, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which one of R₁ and R₂ is hydrogen or lower alkyl and the other of R₁ and R₂ is selected from substituted C₁₋₄alkyl, substituted C₂₋₄alkenyl, substituted C₂₋₄heteroalkyl, aryl, and arylalkyl.
- 15 3. The compound of claim 1, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which R₃ and R₄ are independently hydrogen, alkyl, or arylalkyl.
- 20 4. The compound of claim 1, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which
- W is -C(=O)NHCH(R₂₅)-*t*-butyl or -CH₂C(=O)NHCH(R₂₅)-*t*-butyl;
- L is -C(=O)-, -NHC(=O)-, or -NH-CH₂-;
- R₅, R₆ and R₇ are hydrogen; and
- 25 R₂₅ is hydrogen or hydroxymethyl.
5. The compound of claim 1, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, having the formula (II), in which Z₂ is piperidine.

6. The compound of claim 1, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, having the formula (Ia):



or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which:

- 5 r is 1, 2 or 3.

7. The compound of claim 6, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which

W is $-C(=O)NHCH(R_{25})-t\text{-butyl}$;

10 R_5 , R_6 and R_7 are hydrogen;

R_{25} is hydrogen or hydroxy C_{1-2} alkyl;


R_{23} is hydrogen or oxo ($=O$), and R_{26} is hydrogen or C_{2-6} straight or branched alkenyl, $-OR_{30}$ or $-NR_{31}R_{32}$;

15 R_{30} is C_{1-5} straight or branched chain alkyl, C_{2-6} straight or branched alkenyl, C_{3-5} cycloalkyl, or C_{1-4} straight or branched chain alkyl substituted with one to two of halogen, lower alkoxy, and C_{3-5} cycloalkyl; and

R_{31} and R_{32} are selected from hydrogen and lower alkyl.

8. The compound of claim 7, having the formula:


20



or a pharmaceutically-acceptable salt, hydrate or prodrug thereof.

9. The compound of claim 1, having the formula:

5




or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which

one of R_1 and R_2 is hydrogen, and the other of R_1 and R_2 is phenyl or $-(CH_2)_1$ -phenyl.

10

10. A compound having the formula (I):



or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which:

ring B is phenyl or pyridyl;

W is selected from C_{2-10} alkyl, C_{2-10} alkenyl, substituted C_{2-10} alkyl, substituted C_{2-10} alkenyl,




$-C(=O)NR_9R_{10}$, $-OR_9$, $-CO_2R_9$, $-C(=O)R_9$, $-SR_9$, $-S(O)_pR_9$, $-NR_9R_{10}$,
 $-NR_9SO_2R_{10}$, $-NR_9CO_2R_{10}$, $-NR_9C(=O)R_{10}$, $-SO_2NR_9R_{10}$, heterocyclo, heteroaryl,
 5 aryl, and cycloalkyl;

R_1 and R_2 (i) are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl, heterocyclo, or cycloalkyl; or
 (ii) are taken together to form a five-to-seven membered fully saturated heterocyclo optionally substituted with R_{23} which is hydrogen or oxo ($=O$) and/or one to two R_{26} ;


10 L is $-(CH_2)_s-Y-$;

Y is selected from $-C(=O)-$, $-NHC(=O)-$, $-NH-CH_2-$ and $-CH_2-CH_2-$;

Z_1 is selected from



15




5

10 R_5 and R_6 are independently selected from hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, $-C(=O)H$, acyl, $-CO_2H$, and alkoxycarbonyl, provided that at least one of R_5 and R_6 is hydrogen;

15 R_7 is attached to any available carbon or nitrogen atom of ring Z_1 and is selected from hydrogen, halogen, $-C(=O)NH_2$, $-C(=O)C_{1-4}alkyl$, $-NH_2$, $-NHC_{1-4}alkyl$, $-S-C_{1-4}alkyl$, $-O-C_{1-4}alkyl$, $C_{1-4}alkyl$, $C_{1-4}alkyl$ substituted with NH_2 , and five or six membered heterocyclo or heteroaryl;

- R_8 is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocyclo, cycloalkyl, or alkyl substituted with $-\text{OC}(=\text{O})\text{R}_{24}$ or $-\text{OC}(=\text{O})\text{O}-\text{R}_{24}$, wherein R_{24} is alkyl, substituted alkyl, or cycloalkyl, provided that R_8 is not phenyl when W is methoxy;
- R_9 and R_{10} are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, aryl, heteroaryl, heterocyclo, and cycloalkyl; or alternatively (ii) R_9 and R_{10} may be taken together to form a five-to-seven membered heteroaryl or heterocyclo, except when W is $-\text{S}(\text{O})_p\text{R}_9$, then R_9 is not hydrogen;
- R_{26} and R_{27} (i) are at each occurrence independently selected from hydrogen, OR_{30} , $\text{NR}_{31}\text{R}_{32}$, alkyl, alkenyl, substituted alkyl, substituted alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, alkylthio, $-\text{C}(=\text{O})\text{H}$, acyl, $-\text{CO}_2\text{H}$, alkoxycarbonyl, sulfonamido, sulfonyl, and phenyl, or (ii) two of R_{26} and/or two of R_{27} may be taken together to form a fused benzo ring, a fused heteroaryl, a fused cycloalkyl, or a fused heterocyclo other than a five or six membered heterocyclo having as its heteroatoms two oxygen atoms, provided further that when two R_{26} form a fused benzo ring, then Z is not phenyl substituted in the para position with a five-membered heterocycle or heteroaryl;
- R_{30} at each occurrence is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, and phenyl;
- R_{31} and R_{32} at each occurrence are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, and cycloalkyl;
- m is 0, 1 or 2 when ring B is phenyl and 0 or 1 when ring B is pyridyl;
- p is 1 or 2; and
- s is 0 or 1.
11. The compound of claim 10, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, having the formula:



in which r is 1, 2 or 3.

5


12. The compound of claim 11, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which

W is $-C(=O)NHCH(R_{25})-t\text{-butyl}$ or $-CH_2C(=O)NHCH(R_{25})-t\text{-butyl}$;

L is $-C(=O)-$ or $-NHC(=O)-$; and

10 R_{25} is hydrogen or C_{1-2} hydroxyalkyl.

13. A compound having the formula (IIa):



- 15 or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which:
ring B is phenyl or pyridyl;

W is selected from C_{2-10} alkyl, C_{2-10} alkenyl, substituted C_{2-10} alkyl, substituted C_{2-10} alkenyl,

$-C(=O)NR_9R_{10}$, $-OR_9$, $-CO_2R_9$, $-C(=O)R_9$, $-SR_9$, $-S(O)_pR_9$, $-NR_9R_{10}$,

$-NR_9SO_2R_{10}$, $-NR_9CO_2R_{10}$, $-NR_9C(=O)R_{10}$, $-SO_2NR_9R_{10}$, heterocyclo, heteroaryl,


20 aryl, and cycloalkyl;

X₃ is N or CH;

L is $-(CH_2)_5-Y-$;

Y is selected from $-C(=O)-$, $-NHC(=O)-$, $-NH-CH_2-$ and $-CH_2-CH_2-$;

Z₂ is



R₅ and R₆ are independently selected from hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, $-C(=O)H$, acyl, $-CO_2H$, and alkoxycarbonyl, provided that at least one of R₅ and R₆ is hydrogen;

10 R₇ is attached to any available nitrogen or carbon atom of ring Z₂ and is selected from hydrogen, halogen, $-C(=O)NH_2$, $-C(=O)C_{1-4}alkyl$, $-NH_2$, $-NHC_{1-4}alkyl$, $-S-C_{1-4}alkyl$, $-O-C_{1-4}alkyl$, $C_{1-4}alkyl$, $C_{1-4}alkyl$ substituted with NH_2 , and five or six membered heterocyclo or heteroaryl;

15 R₈ is hydrogen, alkyl, substituted alkyl, heteroaryl, aryl, heterocyclo, cycloalkyl, or alkyl substituted with $-OC(=O)R_{24}$ or $-OC(=O)O-R_{24}$, wherein R₂₄ is alkyl, substituted alkyl, or cycloalkyl, provided that R₈ is not phenyl when W is methoxy;

20 R₉ and R₁₀ are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, aryl, heteroaryl, heterocyclo, cycloalkyl, and cyano; or alternatively (ii) R₉ and R₁₀ may be taken together to form a five-to-seven membered heteroaryl or heterocyclo , except when W is $-S(O)_pR_9$, then R₉ is not hydrogen;

25 R₂₆ and R₂₇ (i) are at each occurrence independently selected from hydrogen, OR₃₀, NR₃₁R₃₂, alkyl, alkenyl, substituted alkyl, substituted alkenyl, halogen, haloalkyl, haloalkoxy, cyano, nitro, alkylthio, $-C(=O)H$, acyl, $-CO_2H$, alkoxycarbonyl, sulfonamido, sulfonyl, and phenyl, or (ii) two of R₂₆ and/or two of R₂₇ may be taken together to form a fused benzo ring, a fused heteroaryl, a fused cycloalkyl, or a fused heterocyclo other than a five or six membered heterocyclo having as its heteroatoms two oxygen atoms;

R_{30} at each occurrence is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, phenyl and benzyl;

R_{31} and R_{32} at each occurrence are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, and cycloalkyl;


5 m is 0, 1 or 2 when ring B is phenyl and 0 or 1 when ring B is pyridyl;

n is 0, 1 or 2;

p is 1 or 2; and

s is 0 or 1.

10 14. A compound according to claim 13 having the formula:



or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which:

R_{26} is C_{2-6} straight or branched alkenyl, $-OR_{30}$ or $-NR_{31}R_{32}$;

15 R_{30} is C_{1-5} straight or branched chain alkyl, C_{2-6} straight or branched alkenyl, C_{3-5} cycloalkyl, or C_{1-4} straight or branched chain alkyl substituted with one to two of halogen, lower alkoxy, and C_{3-5} cycloalkyl; and

R_{31} and R_{32} are selected from hydrogen and lower alkyl.

20 15. The compound of claim 14, or a pharmaceutically-acceptable salt, hydrate or prodrug thereof, in which

W is $-C(=O)NHCH(R_{25})-t\text{-butyl}$ or $-CH_2C(=O)NHCH(R_{25})-t\text{-butyl}$;

L is $-C(=O)-$ or $-NHC(=O)-$; and

R_{25} is hydrogen or C_{1-2} hydroxyalkyl.

16. A pharmaceutical composition comprising (a) at least one compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, and (b) a pharmaceutically acceptable carrier or diluent.

5

17. A pharmaceutical composition for treating an inflammatory or immune disorder comprising (a) at least one compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, (b) at least one second compound for treating an inflammatory or immune disorder, and (c) a pharmaceutically acceptable carrier or
10 diluent.

18. A pharmaceutical composition for treating metastasis comprising (a) at least one compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, and (b) a pharmaceutically acceptable carrier or diluent.

15

19. A pharmaceutical composition for treating a coagulation-associated disorder, an inflammatory or immune disorder or metastasis comprising (i) at least one compound of claim 1 or a pharmaceutically acceptable salt, hydrate or prodrug thereof; (ii) one or more second compounds effective for treating a coagulation-associated disorder, an
20 inflammatory or immune disorder or metastasis; and (iii) a pharmaceutically-acceptable carrier.

20. A method for maintaining a blood supply in the fluid phase comprising administering to said blood supply at least one compound according to claim 1.

25

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number
WO 02/037937 A3

(51) International Patent Classification⁷: C07D 207/16,
211/60, 223/06, 401/12, C07C 257/18, A61K 31/445,
31/55, 31/155, A61P 7/02

(21) International Application Number: PCT/US01/49952

(22) International Filing Date:
7 November 2001 (07.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/246,391 7 November 2000 (07.11.2000) US
60/246,392 7 November 2000 (07.11.2000) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Lawrenceville-Princeton Rd., Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BISACCHI, Gregory, S.** [US/US]; 130 Mountain Road, Ringoes, NJ 08551 (US). **SUTTON, James, C., Jr.** [US/US]; 8 Stonelea Drive, Princeton Junction, NJ 08550 (US). **WU, Shung, C.** [US/US]; 24 Bertrand Dr., Princeton, NJ 08540 (US).

(74) Agents: **ALGIERI, Aldo, A.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Lawrenceville-Princeton Rd., Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


(88) Date of publication of the international search report:
29 August 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS



(I)



(II)

(57) Abstract: Compounds of formula I and II, or pharmaceutically-acceptable salts thereof, are useful as inhibitors of Factor VIIa, Factor IXa, Factor Xa, Factor FXIa, trypsin, and urokinase, wherein ring B is phenyl or pyridyl, L is a linker, and R₁, R₂₇, W, Z₁, and Z₂ are as defined in the specification.

WO 02/037937 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/49952

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D207/16 C07D211/60 C07D223/06 C07D401/12 C07C257/18
A61K31/445 A61K31/55 A61K31/155 A61P7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, BEILSTEIN Data, CHEM ABS Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | WO 99 41231 A (ONO PHARMACEUTICAL CO ; OGAWA KOJI (JP); SENOKUCHI KAZUHIKO (JP)) 19 August 1999 (1999-08-19) cited in the application the whole document | 1-20 |
| E | WO 02 34711 A (BABU YARLAGADDA S ; CHAND POORAN (US); EL KATTAN YAHYA (US); KOTIAN) 2 May 2002 (2002-05-02) see especially definitions of B, E1, E2 and L | 1-20 |
| P, Y | WO 01 70678 A (MERCK PATENT GMBH ; DORSCH DIETER (DE); GLEITZ JOHANNES (DE); JURAS) 27 September 2001 (2001-09-27) see definitions of W and R1 | 1-20 |

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

20 June 2002

Date of mailing of the international search report

03/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | <p>KOVRT J T ET AL: "An efficient synthesis of 2-(3-(4-amidinophenylcarbamoyl)naphthalen- 2-yl)-5-((2,2-methylpropyl)carbamoyl)benzoic acid: a factor VIIa inhibitor discovered by the Ono Pharmaceutical Company" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 41, no. 32, 5 August 2000 (2000-08-05), pages 6041-6044, XP004243509 ISSN: 0040-4039 cited in the application the whole document</p> <p>-----</p> | 1-20 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/49952

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 20 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-7,10-20 (all partly)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-7,10-20 (all partly)

Present claims 1-7,10-20 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds wherein B is phenyl, t is 0 and L is -NH-C(=O)-, -CH₂-CH₂- or -NH-CH₂- and the examples. Furthermore, the term "prodrug thereof" has not been searched, as it is unclear (Article 6 PCT).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/49952

| Patent document cited in search report | | Publication date | | Patent family member(s) | Publication date |
|---|---|---------------------|----|----------------------------|---------------------|
| WO 9941231 | A | 19-08-1999 | AU | 2300699 A | 30-08-1999 |
| | | | EP | 1078917 A1 | 28-02-2001 |
| | | | WO | 9941231 A1 | 19-08-1999 |
| | | | US | 6358960 B1 | 19-03-2002 |
| | | | ZA | 9901273 A | 25-08-1999 |
| WO 0234711 | A | 02-05-2002 | WO | 0234711 A1 | 02-05-2002 |
| WO 0170678 | A | 27-09-2001 | DE | 10014645 A1 | 27-09-2001 |
| | | | WO | 0170678 A2 | 27-09-2001 |

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)